Article Text

Download PDFPDF
Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’
  1. Despina Eleftheriou1,
  2. Michael Levin2,
  3. Delane Shingadia3,
  4. Robert Tulloh4,
  5. Nigel Klein1,
  6. Paul Brogan1
  1. 1 Institute of Child Health and Great Ormond Street, London
  2. 2 Paediatric Infectious Diseases Group, Division of Medicine, Imperial College London
  3. 3 Great Ormond Street Hospital, London
  4. 4 Department of Paediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK
  1. Correspondence to Dr Despina Eleftheriou, Institute of Child Health, 30 Guilford Street, London WC1E1NH, UK; d.eleftheriou{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the letter by Dr Krasseman1 regarding anti-inflammatory doses of aspirin used in the acute phase of Kawasaki disease (KD). Indeed, higher doses of aspirin are currently used in the USA (80–100 mg/kg/day), while in Japan a lower dose of 30–50 mg/kg/day is advocated.2–6 Similarly, in the UK, the latter modest dose has been recommended since 20027 ,8 for the acute phase of KD as a number of previous studies have suggested this lower dose is equally as effective, and may be associated with less toxicity.2 ,4 …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles